* Sana Biotechnology Inc reported a quarterly adjusted loss of 25 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 2 cents. The mean expectation of seven analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -27 cents to -22 cents per share.
* Reported revenue was zero; analysts expected zero.
* Sana Biotechnology Inc's reported EPS for the quarter was a loss of 25 cents.
* The company reported a quarterly loss of $59.92 million.
* Sana Biotechnology Inc shares had fallen by 25.5% this quarter and lost 24.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 9.4% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Sana Biotechnology Inc is 10.00 This summary was machine generated from LSEG data November 8 at 04:14 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.25 -0.25 Met
Jun. 30 2024 -0.28 -0.21 Beat
Mar. 31 2024 -0.32 -0.49 Missed
Dec. 31 2023 -0.38 -0.41 Missed
Comments